Larimar Therapeutics Inc (LRMR)

08:17 AM

What analysts say about Larimar Therapeutics Inc. stockDynamic growth stocks - Autocar Professional

08:17 AM

Jul 23, 2025

What drives Larimar Therapeutics Inc. stock priceRapidly expanding wealth - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Is Larimar Therapeutics Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Larimar Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 23, 2025

Jul 21, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

Jul 21, 2025

Jul 18, 2025

Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Return Investment Tips - Newser

Jul 18, 2025

Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Jul 17, 2025

Jul 16, 2025

5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com

Jul 16, 2025

Jul 15, 2025

Why Larimar Therapeutics Inc. stock attracts strong analyst attentionTop Analyst Picks - Newser

Jul 15, 2025

Jul 15, 2025

What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025

Jul 12, 2025

Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN

Jul 12, 2025

Jul 09, 2025

Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews

Jul 09, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq

Jul 08, 2025

Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan

Jul 08, 2025

Jun 30, 2025

Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 25, 2025

Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN

Jun 25, 2025

Jun 25, 2025

Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) - GuruFocus

Jun 25, 2025

Jun 25, 2025

Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World

Jun 25, 2025

Jun 24, 2025

Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus

Jun 24, 2025

Jun 24, 2025

Larimar Therapeutics (LRMR) Target Price Reduced by Wedbush Amid FDA Delay | LRMR Stock News - GuruFocus

Jun 24, 2025

Jun 24, 2025

Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus

Jun 24, 2025

Jun 23, 2025

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program | LRMR Stock News - GuruFocus

Jun 23, 2025

Jun 21, 2025

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times

Jun 21, 2025

Jun 20, 2025

Larimar Therapeutics Announces Regulatory Update Call on - GlobeNewswire

Jun 20, 2025

Jun 17, 2025

Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus

Jun 17, 2025